Mazdutide

Research Phase

Mazdutide (IBI362)

Aliases
IBI362
Administration
Subcutaneous injection

Documented side effects

Tier 1 · Peer-reviewed / regulatory

GI symptoms (most common)

Nausea, vomiting, or diarrhea are the most frequently reported effects, especially when starting or increasing the dose.

Nausea (common, especially early doses)

Nausea is frequently reported, particularly during the initial loading phase.

Injection site reactions

Mild redness, swelling, or discomfort at the site of injection.